Please login to the form below

Not currently logged in
Email:
Password:

Cidara Therapeutics makes senior appointments

Paul Daruwala and James Balkovec join the biotech

edit-Cidara-Paul-DaruwalaBiotech Cidara Therapeutics has named Paul Daruwala as chief commercial officer and James Balkovec as senior VP of research.

Daruwala (pictured) has over 22 years of experience in the biopharma industry and will lead Cidara's commercial and business development strategies and execution.

He joins from BMS, where he served as VP of the US viral hepatitis franchise, which is responsible for leading the US launch platform in hepatitis C and running the hepatitis B business for Baraclude.

Prior to BMS, Daruwala spent 18 years at Merck in a range of US and global commercial leadership roles in areas including anti-inflammatory products, business development and sales management.

Balkovec has over 28 years of experience in the biopharma industry and has extensive experience within drug discovery. He also joins from Merck, where he has served as senior scientific director and team leader, managing programmes in areas including infectious disease, metabolic syndrome and thrombosis disease.

Balkovec has helped bring more than a dozen development candidates into clinical development, including the first approved echinocandin antifungal drug Cancidas (caspofungin), which he is additionally co-inventor of.

Cidara focuses on the discovery, development and commercialisation of novel anti-infectives for the treatment of diseases that are not adequately addresses by current available therapies.

2nd March 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics